SecBot SecBot
SECBOTREPLAY Home › Report › HOWL

HOWL · WTX-124/330 SITC data

Werewolf Therapeutics, Inc. · 8-K filed Nov 9, 2026 at 09:22 ET

At the news

NEUTRALIMPACT 5/10

8-K filed Nov 9, 2026 at 09:22 ET

Werewolf Therapeutics presented new clinical data at SITC 2026 for its two lead drug candidates, WTX-124 (IL-2 prodrug) and WTX-330 (IL-12 prodrug), in Phase 1/1b and Phase 1b/2 trials for solid tumors. The data showed safety in the outpatient setting, no vascular leak syndrome, and antitumor activity in heavily pretreated patients, including confirmed responses. The company also announced FDA alignment on a recommended Phase 2 dose of 18 mg IV Q2W for WTX-124.

  • WTX-124 Phase 1/1b data from 155 patients showed objective responses including a durable complete response in CSCC and partial responses in melanoma and GEJ adenocarcinoma.
  • WTX-124 in combination with pembrolizumab produced a 37.5% response rate in NSCLC and a 15.8% response rate in cutaneous melanoma in dose expansion.
  • FDA aligned on WTX-124 recommended Phase 2 dose of 18 mg IV Q2W for monotherapy and combination with pembrolizumab.
  • WTX-330 Phase 1b/2 data from 24 patients showed a confirmed partial response in gallbladder cancer and evidence of intratumoral IL-12/STAT4 signaling in 7 of 9 paired biopsies.

Replay the market's reaction

Step through every 5 minutes around the news, then see how it compares with similar events.

Subscribe for Full Access